Chronic obstructive pulmonary disease is one of the world’s top drivers of chronic disease burdens, the chief executive officer of ResMed told the JP Morgan Healthcare Conference, as he explained the company’s strategy to help meet unmet needs using digital connectivity and data analytics.
Chronic obstructive pulmonary disease is one of the world’s top drivers of chronic disease burdens, the chief executive officer of ResMed told the JP Morgan Healthcare Conference, as he explained the company’s strategy to help meet unmet needs using digital connectivity and data analytics.
Michael Farrell laid out the company’s strategy to 2025 by outlining the macro and micro trends affecting the company, which makes connected devices for respiratory care.
Besides the growing burden of chronic disease, the world is aging rapidly, he said. “Nine percent of the world’s population is over age 65 or older,” said Farrell. “By 2050 that will double to almost 17% of the world’s population being of retirement age.”
He called aging a “global epidemic” that will collide with soaring healthcare costs as well as a shortage of physicians. On a micro level, Farrell said he thinks the company can impact those trends by delivering the correct care when needed at the right time and in lower-cost settings outside of the hospital.
The company has a goal to impact 250 million lives with out-of-hospital care by 2025, Farrell said. “We think hospitals are places where sick care happens,” he said, adding that most people would rather be at home or in other settings.
COPD is the third-leading cause of death worldwide, he said, and the second cause of hospital readmissions. According to the company, more than 380 million people worldwide are estimated to have COPD, and in some countries—mainly in India, Brazil, China, and Eastern Europe—it may be undiagnosed, Farrell said. COPD causes about 3 million deaths per year, he said.
ResMed wants to change the lives of patients with COPD by creating new solutions for unmet needs. That includes making its portable oxygen concentrators connected in order to gather COPD data, he said.
Farrell also highlighted the company’s recent purchase of Propeller Health, which he said gives ResMed data on inhaled medicines. Propeller makes digital sensors that attach to respiratory devices and captures patient data. In COPD, the sensors have been shown to document a 59% reduction in healthcare utilization, an increase in symptom-free days, and a reduction in medication use, he said.
The deal allows ResMed to scale Propeller’s digital health around the world, Farrell said.
Patient-Reported Outcomes Help to Uncover Frailty Patterns in Those With Acute COPD Exacerbations
April 22nd 2024Study findings demonstrate the pivotal role of patient-reported outcomes in identifying frailty among individuals experiencing acute exacerbations of chronic obstructive pulmonary disease (COPD).
Read More
A Pulmonologist on Why You Should Think About Respiratory Health and the Lungs
November 16th 2021On this episode of Managed Care Cast, we speak with MeiLan K. Han, MD, MS, the author of a book released this month called Breathing Lessons: A Doctor’s Guide to Lung Health. Han, a pulmonologist, gives an inside tour of the lungs and how they work, zooms out to examine the drivers of poor respiratory health, and addresses policy changes that are needed to improve lung health.
Listen
Study: Decreased BMI Increases Severe Exacerbation, All-Cause Mortality Risk in Patients With COPD
April 10th 2024Decreased body mass index (BMI) in patients with chronic obstructive pulmonary disease (COPD) was linked to a higher risk of severe exacerbations and all-cause mortality, emphasizing the importance of monitoring BMI for managing COPD and predicting outcomes.
Read More
Dose-Escalation, Low-Dose Regimens May Improve Roflumilast Treatment Adherence in Patients With COPD
March 24th 2024This study suggests that dose-escalation or low-dose regimens for roflumilast treatment in patients with chronic obstructive pulmonary disease (COPD) may improve adherence.
Read More